This investment company faced a challenging year with a 9.5% decline in NAV per share and a 17% negative return on its life science portfolio, reflecting broader biotech sector headwinds and volatile market conditions.
The asset management firm is undertaking a strategic review and proposing changes to its investment objective and policy to maximize shareholder value.
The biopharmaceutical company Autolus, a portfolio company of Syncona, will present updated long-term data on its obe-cel therapy for r/r B-ALL at the EHA Congress.
The investment company has received a notification of a change in shareholding from BlackRock, Inc.
The biotechnology company presents positive data on its gene therapy programs for Gaucher disease, Parkinson's disease, and adrenomyeloneuropathy at a medical conference.
The biopharmaceutical company reported robust Q1 2025 results, including $9.0 million in net product revenue, and obtained UK marketing authorization for its lead product AUCATZYL.
The biotechnology company reports positive interim results from a Phase II trial of its gene therapy for a rare inherited retinal disease.
The targeted oncology therapeutics company Mosaic Therapeutics has in-licensed two clinical-stage assets from Astex Pharmaceuticals, accelerating its development pipeline.
The biopharmaceutical company reports full year 2024 financial results, including increased cash position and progress on the commercial launch of its lead product AUCATZYL.
The asset management firm has announced a change in major shareholding, with the Wellcome Trust increasing its stake in the company.